Haemonetics ( (HAE) ) has released its Q4 earnings. Here is a breakdown of the information Haemonetics presented to its investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Haemonetics Corporation is a global medical technology company specializing in innovative healthcare solutions, including hospital technologies, plasma collection systems, and blood center products. In its latest earnings report for the fourth quarter and fiscal year 2025, Haemonetics reported a mixed financial performance with a 4% increase in annual revenue to $1.361 billion, despite a 3.7% decline in fourth-quarter revenue compared to the previous year. The company achieved a record gross margin expansion and strong cash flow, with earnings per diluted share reaching $3.31 for the fiscal year. Key highlights include a significant increase in the hospital segment’s revenue and a decrease in plasma and blood center revenues. The company also completed a $300 million share repurchase program and announced a new $500 million authorization to offset the impact of employee equity grants. Looking ahead, Haemonetics is focused on achieving its long-term growth plans, with fiscal 2026 guidance indicating continued strategic investments and potential revenue growth in the hospital segment.